Nvidia (NVDA) announced its first microprocessor for the server market today, April 12. Right now Intel (INTC) owns around 90% of the market for server processors. And the company also reported that first-quarter revenue “is tracking” above its previous forecast. Revenue in the quarter ending in April is now expected to be higher than $5.3 the billion, which Nvidia projected on February 24. Nvidia shares were up 5.62% today on the news
Looking at the recent performance numbers on the 20 stocks I’m tracking in my Dip-O-Meter as of the close on Friday April 9, I have to conclude that for most of these stocks it’s time to take a pause on any “buy on the dip” opportunities. What I’m seeing in this sample is a general weakening of the upward bounce on rally days from these stocks–and without a strong bounce on a good day there’s not much reason to buy on the dip.
This buy on the dip moment is over–this week’s revision of my Dip-O-Meter argues to me. The discounts to the February highs are, in general, getting smaller. And in many cases the size of the bounce that I’m seeing on up days is decreasing too.
Today, I’m going to review the fundamental case for Wyndham shares (the reason I added it to Jubak Picks on March 17) and give you the details on the Call Option on Wyndham that I’ll be adding to my Volatility Portfolio tomorrow.
Shares of Chargepoint (CHPT) were up 15.40% as of 2:30 p.m. New York time today, March 31. Charging station competitor Blink Charging (BLNK) was up 8.69%. The big jump came on speculation that the Biden administration’s infrastructure plan with its emphasis on growing the number of electric vehicles in use would include incentives and money for expanding the woefully inadequate U.S. network of charging stations for electric cars.
The one certainty in the stock market right now, I’d say, is volatility. Both to the upside and to the downside. So I think we should take what the market is giving us. Using these three moves in the short term.
I’ve scrubbed through the 20 stocks in the Dip-O-Meter, with updated numbers as of the close on Friday, March 26, looking for the best three buy on the dip trades. (Why only three? Because I think the same volatility that has created these profit opportunities makes it hard to be certain of a trend and I don’t want to bet the farm with the current degree of uncertainty. My choices for trades that I’ll put on tomorrow in my Volatility Portfolio are SunRun (RUN), Teladoc (TDOC), and PayPal (PYPL). These are all going into my Volatility Portfolio
Tomorrow, March 24, I’m going to add another hedge against a drop in stock prices, one that’s a more general market hedge against a more general market decline. The hedge is the September 17 Put Option (which goes up in price as the share price goes down) on the small cap Russell 2000 Index using the iShares MSCI Russell 2000 ETF.
You’ve read this story before (in fact many times before) in the last month or so. Tech stocks rebounded after a day or two of selling. What was different (because it wasn’t a case of rotation but a continuation of a recent trend) was the continued drop in the CBOE S&P 500 Volatility Index (VIX) to 18.88, a decrease of 9.88%
Hedges that can pay off on the downside and the upside are the most useful and most valuable. They also tend to be relatively rare. There aren’t a lot of these bets floating around in most markets just waiting for you to snap them up. However, I have found two hedges of just this sort in today’s market that I’m going to recommend to you today. (In this post I’m going to give you some of the nitty gritty numbers that support my recommendation for these two hedges. If you want to see some charts for copper and gold, banks and bonds check out the video I posted today.) I’m going to add these new recommendations to my standing Special Reports post tomorrow.
Shares of biotech stock Incyte (INCY) have been down significantly in 2021. For the year to date, as of the close on March 2, the shares were down 8.45%. In the last month they’ve tumbled 12.42%. So what’s wrong? Pretty much nothing. With the individual stock anyway. What we’re watching is a lot of selling in the biotech sector as part of the recent sell-off on risk. And on substantial profit taking.
On to Stage #2 in my Special Report: “Profit and Protect–What you need to know about stock market stages for 2021. And to my rules for the sells and hedges in Stage #2 for 2021: When you win, you lose. (I just posted sells for ILMN, CTVA, WST and VMW)